Medical Pharmacology: Immunopharmacology (Immunosuppressants/Immunomodulators) Practice Questions
Vendolizumab (Entyvio)
Click on the correct answer.
Vendolizumab (Entyvio):
Monoclonal antibody
May be appropriate (approved for use) in adults diagnosed with moderate to severe ulcerative colitis
Both
Neither
Vedolizumab in treating ulcerative colitis: appropriate for individuals exhibiting moderate to severe active disease when TNF-α antagonists or conventional treatment proved ineffective.
True
False
Vendolizumab:
Human monoclonal antibody
Targets gastrointestinal tract integrin (α4β7)
Both
Either
Vendolizumab:
Often induces systemic immunosuppression
of other α4β7 integrins.
Binds to most
α4β7 lymphocyte integrins.
Both
Neither
Vendolizumab may be used in treating moderate-to severe active Crohn's when:
Conventional therapy proved ineffective was not tolerable by the patient.
When TNF-α antagonists were not effective
Both
Neither
Vendolizumab may be effective in treating "steroid refractory checkpoint inhibitor induce colitis under circumstance in which infleximab is either not appropriate" (contraindicated) or ineffective.
True
False
Vedolizumab pharmacokinetics:
Administration: intravenous infusion
At low concentration: vendolizumab exhibits a target-mediated elimination process (rapid, saturable, non-linear)
Both
Neither
Vendolizumab:
Gut-selective α4β7 integrin antagonists
Vedolizumab acts by blocking adhesion of memory T cells to mucosal addressin cell adhesion molecule-1
Both
Neither
Vedolizumab reduces inflammatory cell infiltration into gut mucosal tissue and is the result reduces gut inflammation.
True
False
Vendolizumab linear clearance: similar in both ulcerative colitis and Crohn's disease patient groups.
Rothlin C Gutkind J Chapter 39
Immunosuppressants, Immunomodulation and Tolerance In
Goodman & Gilman's The Pharmacological Basis of Therapeutics
(Brunton LL Knollman BC eds) McGraw Hill LLC (2023).
Lake D & Briggs A Ch 55 Immunopharmacology
in Katzung's Basic & Clinical Pharmacology (Vanderah TW, ed)
16e McGraw Hill 2023.
Rosario M Dirks N Milch C Parikh A
Bargfrede M Wyant T Fedyk E Fox I A Review of the Clinical
Pharmacokinetics, Pharmacodynamics, and Immunogenicity of
Vendolizumab Clin Pharmacokinet 2017 18; May 56(11):
1287-1301
https://pmc.ncbi.nlm.nih.gov/articles/PMC5648740/
Chrouos G Ch 39 Adrenocorticosteroids &
Adrenocortical Antagonists in Katzung's Basic & Clinical
Pharmacology (Vanderah TW, ed) 16e McGraw Hill 2023
Brezinski E Klickstein L Armstrong A Ch 46
Pharmacology of Immunosuppression in Principles of
Pharmacology: The Pathophysiologic Basis of Drug Therapy.
(Golan DE Armstrong EJ Armstrong AW, eds) 4e
2017
Ritter JM Flower R Henderson G Loke YK
MacEwan D Robinson E Fullerton J Ch 25 Anti-inflammatory and
Immunosuppressant Drugs Rang & Dale's Pharmacology 10e
Elsevier 2024.
Burchum J Rosenthal L Lehne's Pharmacology
for Nursing Care Ch 72 Immunosuppressants Elsevier 2022.
Burchum J Rosenthal L Lehne's Pharmacology
for Nursing Care Ch 75 Glucocorticoids in Nonendrocrine
Disorders Elsevier 2022.
Burchum J Rosenthal L Lehne's Pharmacology
for Nursing Care Ch 76 Drug Therapy for Rheumatoid Arthritis
Elsevier 2022.
Bass A Rogatsky Ch 32 Immunomodulatory Drugs
in Goldman-Cecil Medicine (Goldman L Schafer, eds) Elsevier
26e 2020
Leiva M Takemoto Ch 238 Immunosuppressants in
Lippincott Illustrated Reviews: Pharmacology 8e ((Walen et
al, eds) Wolters Kluwer 2023.
Hall J Hall M Ch 78 Adrenocortical
Hormones Guyton and Hall Textbook of Medical Physiology 14e
Elsevier 2021.
Waller DG Sampson A Hitchings Ch 38 The
Immune Response and Immunosuppressant Drugs
Medical Pharmacology & Therapeutics 6e Elsevier 2022
Waller DG Sampson A Hitchings Ch 30
Rheumotoid Arthritis, Other Inflammatory Arthrides and
Osteoarthritis Medical Pharmacology & Therapeutics 6e
Elsevier 2022